Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
7
pubmed:dateCreated
1992-7-10
pubmed:abstractText
Vaccines prepared from the envelope glycoprotein, gp120, of the common laboratory isolate of human immunodeficiency virus type 1 (HIV-1) (IIIB/LAV-1) elicit antibodies that neutralize the homologous virus but show little if any cross-neutralizing activity. This may be because the principal neutralizing determinant (PND) of gp120 is highly unusual in the IIIB/LAV-1 strain and is not representative of those found in the majority of field isolates. We have now examined the immunogenicity of recombinant gp120 prepared from the MN strain of HIV-1 (MN-rgp120), whose PND is thought to be representative of approximately 60% of the isolates in North America. Our results show that MN-rgp120 is a potent immunogen and elicits anti-gp120 titers comparable to those found in HIV-1-infected individuals. While both MN-rgp120 and IIIB-rgp120 induced antibodies able to block gp120 binding to CD4, strain-specific and type-common blocking antibodies were detected. Finally, antibodies to MN-rgp120 but not to IIIB-rgp120 were effective in neutralizing a broad range of laboratory and clinical isolates of HIV-1. These studies demonstrate that susceptibility or resistance to neutralization by antibodies to gp120 correlates with the PND sequence and suggest that the problem of antigenic variation may not be insurmountable in the development of an effective AIDS vaccine.
pubmed:commentsCorrections
http://linkedlifedata.com/resource/pubmed/commentcorrection/1602554-1370525, http://linkedlifedata.com/resource/pubmed/commentcorrection/1602554-1700435, http://linkedlifedata.com/resource/pubmed/commentcorrection/1602554-1702163, http://linkedlifedata.com/resource/pubmed/commentcorrection/1602554-1703322, http://linkedlifedata.com/resource/pubmed/commentcorrection/1602554-1720630, http://linkedlifedata.com/resource/pubmed/commentcorrection/1602554-1724568, http://linkedlifedata.com/resource/pubmed/commentcorrection/1602554-1727480, http://linkedlifedata.com/resource/pubmed/commentcorrection/1602554-1768462, http://linkedlifedata.com/resource/pubmed/commentcorrection/1602554-1988952, http://linkedlifedata.com/resource/pubmed/commentcorrection/1602554-2014634, http://linkedlifedata.com/resource/pubmed/commentcorrection/1602554-2190095, http://linkedlifedata.com/resource/pubmed/commentcorrection/1602554-2355006, http://linkedlifedata.com/resource/pubmed/commentcorrection/1602554-2370681, http://linkedlifedata.com/resource/pubmed/commentcorrection/1602554-2392685, http://linkedlifedata.com/resource/pubmed/commentcorrection/1602554-2431324, http://linkedlifedata.com/resource/pubmed/commentcorrection/1602554-2432599, http://linkedlifedata.com/resource/pubmed/commentcorrection/1602554-2441877, http://linkedlifedata.com/resource/pubmed/commentcorrection/1602554-2450351, http://linkedlifedata.com/resource/pubmed/commentcorrection/1602554-2452447, http://linkedlifedata.com/resource/pubmed/commentcorrection/1602554-2454471, http://linkedlifedata.com/resource/pubmed/commentcorrection/1602554-2455898, http://linkedlifedata.com/resource/pubmed/commentcorrection/1602554-2550139, http://linkedlifedata.com/resource/pubmed/commentcorrection/1602554-271968, http://linkedlifedata.com/resource/pubmed/commentcorrection/1602554-3014647, http://linkedlifedata.com/resource/pubmed/commentcorrection/1602554-3261775, http://linkedlifedata.com/resource/pubmed/commentcorrection/1602554-3392769
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jul
pubmed:issn
0022-538X
pubmed:author
pubmed:issnType
Print
pubmed:volume
66
pubmed:owner
NLM
pubmed:authorsComplete
N
pubmed:pagination
4464-9
pubmed:dateRevised
2009-11-18
pubmed:meshHeading
pubmed:year
1992
pubmed:articleTitle
Neutralization of multiple laboratory and clinical isolates of human immunodeficiency virus type 1 (HIV-1) by antisera raised against gp120 from the MN isolate of HIV-1.
pubmed:affiliation
Department of Immunobiology, Genentech, Inc., South San Francisco, California 94080.
pubmed:publicationType
Journal Article